# US 2025/0177453 A1 · Compositions and methods for enhancing immune tolerance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0177453 A1
- Document ID: US20250177453A1
- Status: Published application
- Kind: A1
- Application number: 18/942,086
- Filed: 2024-11-08
- Published: 2025-06-05
- Earliest claimed: 2022-05-10
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Douglas A. Melton; Dario Gerace; Quan Zhou
- Web page: https://patentgrep.com/patent/US20250177453A1

## CPC

- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 40/10: characterised by the cell type used
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/4229: {Transforming growth factor [TGF]}
- A61K 40/4234: {Interleukins [IL]}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/495: Transforming growth factor [TGF]
- C07K 14/55: IL-2
- C12N 5/0676: {Pancreatic cells}
- C12N 2502/1164: NK cells
- C12N 2502/22: pancreatic cells
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are methods of producing a hypoimmune cell and methods of mediating localized immune tolerance.

## Claims

### Claim 1

A hypoimmunogenic cell engineered to express one or more tolerogenic transgenes from one or more loci in the stem cell or progenitor cell which is not silenced during differentiation of the stem cell or progenitor cell to a desired differentiated cell type.

### Claim at position 2

-16. (canceled)

### Claim 17

A method of producing a hypoimmunogenic cell comprising engineering a stem cell or progenitor cell to express one or more tolerogenic transgenes from a locus in the stem cell or progenitor cell which is not silenced during differentiation of the cell to a desired cell type and exposing the stem cell or progenitor cell to conditions suitable for the stem cell or progenitor cell to differentiate to a desired cell type.

### Claim at position 4

-32. (canceled)

### Claim 33

A method of mediating localized immune tolerance comprising engineering a stem cell or progenitor cell to express one or more immunomodulatory agents from a locus in the stem cell or progenitor cell which is not silenced during differentiation of the cell to a desired cell type and exposing the stem cell or progenitor cell to conditions suitable for the stem cell or progenitor cell to differentiate to a desired cell type, thereby producing a desired cell type that secretes said one or more immunomodulatory agents.

### Claim at position 6

-45. (canceled)

### Claim 46

A cell engineered to express one or more immunomodulatory agents from one or more loci in a stem cell or progenitor cell which is not silenced during differentiation of the stem cell or progenitor cell to a desired differentiated cell type, wherein the one or more immunomodulatory agents is selected from the group consisting of IL-10, TGF-β and IL-2 or a modified IL-2.

### Claim 47 (depends on 46)

A cell according to claim 46, wherein the cell is a stem cell.

### Claim 48 (depends on 46)

A cell according to claim 46, wherein the cell is an induced pluripotent cell.

### Claim 49 (depends on 46)

A cell according to claim 46, wherein the cell is a progenitor cell.

### Claim 50 (depends on 46)

A cell according to claim 46, wherein the cell is a beta cell progenitor cell.

### Claim 51 (depends on 46)

A cell according to claim 46, wherein the cell is a differentiated cell.

### Claim 52 (depends on 46)

A cell according to claim 46, wherein the cell is a beta cell.

### Claim 53 (depends on 46)

A cell according to claim 46, wherein the cell is an alpha cell.

### Claim 54 (depends on 46)

A cell according to claim 46, wherein the cell is an islet cell.

### Claim 55 (depends on 46)

A cell according to claim 46, wherein the one or more loci is the locus of a housekeeping gene.

### Claim 56 (depends on 55)

A cell according to claim 55, wherein the housekeeping gene is selected from the group consisting of actin, ubiquitin, and GAPDH.

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59 (depends on 17)

A cell produced by the method of claim 17.

### Claim 60 (depends on 33)

A cell produced by the method of claim 33.

### Claim 61 (depends on 1)

A method of treating a subject in need thereof comprising administering to the subject a cell according to claim 1.

### Claim 62 (depends on 46)

A method of treating a subject in need thereof comprising administering to the subject a cell according to claim 46.
